Espicom


The Pharmaceutical Market: Chile

Published 08 October 2014

  • 129 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
The Pharmaceutical Market: Chile

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
13
Business Environment
14
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Chile 2010-2018)
16
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Chile 2010-2018)
18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Chile 2010-2018)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Chile 2010-2018)
20
Prescription Drug Market Forecast
21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Chile 2010-2018)
22
Patented Drug Market Forecast
23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Chile 2010-2018)
24
Generic Drug Market Forecast
25
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Chile 2010-2018)
26
OTC Medicine Market Forecast
27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Chile 2010-2018)
28
Pharmaceutical Trade Forecast
29
Table: Pharmaceutical Trade Data And Forecasts (Chile 2012-2018)
31
Table: Pharmaceutical Trade Data And Forecasts local currency (Chile 2012-2018)
31
Other Healthcare Data
32
Key Risks To BMI's Forecast Scenario
33
Macroeconomic Forecasts
34
Economic Analysis
34
Table: Chile - Economic Activity
42
Industry Risk Reward Ratings
43
Americas Risk/Reward Ratings
43
Chile Risk/Reward Ratings
49
Rewards
49
Risks
50
Market Overview
51
Industry Trends And Developments
52
Epidemiology
52
Healthcare Sector
54
Table: Isapres Beneficiaries, 1990-2009
56
Table: Beneficiaries by Isapre Type, 2009
57
Healthcare Sector Developments
62
Table: Physicians by Specialty, 2000-2009
65
Healthcare Insurance
65
Research And Development
68
Clinical Trials
70
Regulatory Development
72
Regulatory Regime
72
Regulatory Developments
73
Table: Latin American Regulations On Bioequivalence And GMP
80
Intellectual Property Issues
81
Trade Agreements
84
Pricing Regime
85
Public Procurement
86
Table: Pharmaceutical Price Build-up (%)
87
Reimbursement Regime
88
Competitive Landscape
90
Pharmaceutical Sector
90
Domestic Industry
90
Foreign Industry
91
Pharmaceutical Distribution
93
Pharmaceutical Retail Sector
93
Table: Pharmacy Sales Value by Sector, 2007-2008 (USDmn)
97
Company Profile
98
Laboratorios Chile (LabChile)
98
Corporaci-n Farmac-utica Recalcine (CFR)
101
Laboratorios Andr-maco
105
Pfizer
109
Novartis
111
Sanofi
113
GlaxoSmithKline
115
Merck & Co
117
Other Company Developments
118
Demographic Forecast
120
Table: Chile's Population By Age Group, 1990-2020 ('000)
121
Table: Chile's Population By Age Group, 1990-2020 (% of total)
122
Table: Chile's Key Population Ratios, 1990-2020
123
Table: Chile's Rural And Urban Population, 1990-2020
123
Glossary
124
Methodology
126
Pharmaceutical Expenditure Forecast Model
126
Healthcare Expenditure Forecast Model
126
Notes On Methodology
127
Risk/Reward Ratings Methodology
128
Ratings Overview
129
Table: Pharmaceutical Risk/Reward Ratings Indicators
129
Indicator Weightings
130
OVERVIEW OF THE PHARMACEUTICAL MARKET IN CHILE

Pharmaceutical companies will continue to look to fast growing emerging markets for revenue growth, and we believe that Latin American economies, with rising incomes, ageing populations and increased spending on healthcare will provide significant opportunities. Indeed, it is our view that emerging markets will be the main drivers of the pharmaceutical sector's expansion over the coming years as growth in traditional markets such as the US, Western Europe and Japan remains lacklustre. We note however, that imported patented and high-cost drugs, mostly originating from Europe and the US, account for a significant portion of the Latin American pharmaceutical market in terms of value.

Headline Expenditure Projections

Pharmaceuticals: CLP1,508bn (US$3.12bn) in 2011 to CLP1,642bn (US$3.22bn) in 2012; +8.9% in local currency terms and +3.3% in US dollar terms.

Healthcare: CLP9,034bn (US$18.67bn) in 2011 to CLP9,941bn (US$19.49bn) in 2012; +10.0% in local currency terms and +4.4% in US dollar terms.

Medical devices: CLP256.33bn (US$530mn) in 2011 to CLP267.45bn (US$525mn) in 2012; +4.3% in local currency terms and -1.0% in US dollar terms.


Risk/Reward Rating

In Q4 12's America's pharmaceutical risk/reward ratings (RRRs) matrix, Chile ranks in seventh place out of the 17 countries surveyed, scoring a total of 53.7 out of 100. We expect Chile, which has a favourable rewards profile, to climb up the regional matrix over the coming years as operational risks become addressed. In the Q412 RRRs, with regards to the country's attractiveness to innovative drug companies, Chile stands above Argentina and Peru and below Mexico and Brazil.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%